Tepotinib - Merck
Alternative Names: EMD-1214063; MSC-2156119; MSC-2156119J; TEPMETKOLatest Information Update: 31 Aug 2026
At a glance
- Originator EMD Serono; Merck KGaA
- Class Antineoplastics; Benzonitrile; Piperidines; Pyridazines; Pyrimidines; Small molecules
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Yes - Non-small cell lung cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase II Colorectal cancer; Liver cancer
- Discontinued Solid tumours
Most Recent Events
- 15 Jul 2026 Merck KGaA completes a phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in the USA, Belgium, China, France, Germany, Hong Kong, Italy, Japan, Malaysia, Netherlands, Russia, Singapore, South Korea, Spain, Taiwan, Thailand and Vietnam (PO) (NCT03940703) (EudraCT2019-001538-33)
- 02 Jun 2026 Updated efficacy and adverse event data from the phase II VISION trial in Non-small cell lung cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 29 May 2026 Pharmacodynamic data from the phase II VISION trial in Non-small cell lung cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)